MyomoMYO
MYO
About: Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Employees: 106
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
725% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 4
439% more call options, than puts
Call options by funds: $399K | Put options by funds: $74K
139% more capital invested
Capital invested by funds: $39.4M [Q3] → $94.1M (+$54.7M) [Q4]
71% more funds holding
Funds holding: 41 [Q3] → 70 (+29) [Q4]
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
11.41% more ownership
Funds ownership: 32.54% [Q3] → 43.95% (+11.41%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9
57%
upside
Avg. target
$9
57%
upside
High target
$9
57%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Craig Knickerbocker 50% 1-year accuracy 1 / 2 met price target | 57%upside $9 | Buy Maintained | 13 Dec 2024 |
Financial journalist opinion
Positive
MarketBeat
2 weeks ago
3 Underrated Robotics Stocks Poised for Major Growth
The days of robots being primarily limited to manufacturing applications are long gone—the industry is expanding rapidly and becoming integrated into many different sectors thanks to rapid developments in AI and automation. Analysts expect this to lead to major growth for the industry in the years to come, with an anticipated CAGR of more than 15% in the coming seven years to reach a size of nearly $170 billion globally by 2032.
Positive
MarketBeat
2 months ago
Top 3 Cutting-Edge Micro-Caps Set for 2025 Growth
As 2025 approaches, several promising micro-cap stocks are gaining attention for their potential to disrupt key industries. These companies, though small in market size, are making significant strides with innovative technologies and strategic advancements.
Neutral
Business Wire
2 months ago
Myomo, Inc. Prices $15.0 Million Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has priced an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $5.00 per share. Myomo expects the gross proceeds from this offering to be approximately $15.0 million, before deducting the underwriting discount.
Neutral
Business Wire
2 months ago
Myomo, Inc. Announces Proposed Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, Myomo also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in t.
Neutral
Seeking Alpha
3 months ago
Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript
Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
3 months ago
Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.06 per share a year ago.
Neutral
Business Wire
3 months ago
Myomo Reports Record Third Quarter Financial and Operating Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2024. Financial and operating highlights for the third quarter of 2024 include the following (all comparisons are with the third quarter of 2023 unless otherwise indicated): Product a.
Positive
Seeking Alpha
3 months ago
CMS Decision And O&P Network Build Out Make Myomo A Buy
Myomo's business model is now sustainable due to CMS reclassifying MyoPro, leading to lump sum payments and consistent insurance coverage. Medicare Part B coverage has significantly improved Myomo's operating margin and accelerated its product sales growth. The development of an Orthopedic and Prosthetic clinic network will lower customer acquisition costs and create recurring sales, enhancing long-term growth & margins.
Neutral
Business Wire
3 months ago
Myomo Announces First Private Payer Contracts for MyoPro In-network Coverage
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces it has entered into the first contracts that will allow MyoPro to be provided to patients covered by private insurance on an in-network basis. These new contracts are with Blue Cross Blue Shield of Massachusetts, a leading commercial and Medicare Advantage.
Neutral
Business Wire
3 months ago
Myomo to Report Third Quarter Financial Results on November 6, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the third quarter ended September 30, 2024 on November 6, 2024. The Company will host a conference call the same day, Wednesday November 6, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairm.
Charts implemented using Lightweight Charts™